View clinical trials related to Virus Diseases.
Filter by:The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and who are not eligible to enroll in clinical studies designed to support the development and registration of tabelecleucel.
This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.